Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-033
- Development stage
- Phase 1
- Lead developer
- 普祺医药
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PG-033 is an investigational small molecule drug developed by Beijing Puqi Pharmaceutical Technology. It is currently in early clinical development, with its highest global R&D status being Phase 1. The primary indication under investigation for PG-033 is pruritus (itch), a symptom associated with various skin and musculoskeletal diseases. The drug is being evaluated for its safety, tolerability, and pharmacokinetics in healthy adults through single ascending dose studies and food effect studies. As of June 2025, there are no publicly available details on the specific molecular target or mechanism of action for PG-033[1][2][3][4].
Beyond the preview
Go deeper on PG-033.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PG-033.